title: Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer.
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Edmund C P
authors.initials: EC
authors.lastname: Chedgy
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Institute of Biosciences and Medical Technology, Tampere, Finland.
authors.forename: Matti
authors.initials: M
authors.lastname: Annala
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Kevin
authors.initials: K
authors.lastname: Beja
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Evan W
authors.initials: EW
authors.lastname: Warner
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gleave
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Kim N
authors.initials: KN
authors.lastname: Chi
authors.affiliation: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: awaytt@prostatecentre.com.
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Wyatt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D024682:BRCA2 Protein / Q000235:genetics*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D017353:Gene Deletion; D006801:Humans; D008297:Male; D008875:Middle Aged; D057285:Precision Medicine; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D002945:Cisplatin
keywords: Cell-free DNA; DNA damage repair; Precision medicine; Small cell carcinoma; ctDNA